Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $10.1000 (2.64%) ($9.9900 - $10.6400) on Tue. Apr. 7, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.2% (three month average) | RSI | 67 | Latest Price | $10.1000(2.64%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 1.8% a day on average for past five trading days. | Weekly Trend | FOLD advances 4.6% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(55%) XBI(52%) IWO(51%) IWM(46%) IWC(44%) | Factors Impacting FOLD price | FOLD will decline at least -3.6% in a week (0% probabilities). VIXM(-29%) VXX(-15%) UUP(-11%) TLT(-4%) UNG(-3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.6% (StdDev 7.2%) | Hourly BBV | 0 () | Intraday Trend | -0.2% | | | |
|
5 Day Moving Average | $9.55(5.76%) | 10 Day Moving Average | $9.5(6.32%) | 20 Day Moving Average | $8.88(13.74%) | To recent high | -9.5% | To recent low | 52.3% | Market Cap | $2.608b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |